Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Calian Group Ltd
T.CGY
Alternate Symbol(s):
CLNFF
Industrials
Calian Group Ltd. is a diverse solutions company. The Company is engaged in providing healthcare, communications, learning and cybersecurity products and services. It provides business services and solutions to both industry and government customers in the areas of health, learning, defense, security, aerospace, engineering, and information technology (IT). Its Advanced Technologies segment is a supplier of technical solutions, services and products to the aerospace and defense, satellite, wired and terrestrial wireless, agricultural technology, and nuclear industries. The Health segment delivers healthcare and digital health solutions. The ITCS segment includes on-demand resourcing, IT and cybersecurity consulting, managed services, and software as a service. Its Learning segment provides training as a service, emergency management solutions, and custom training solutions. It also offers a full suite of services from design, installation and teleport services to satellite operations.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSX:CGY - Post by User
Calian Group Ltd
<< Previous
Bullboard Posts
Next >>
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 20, 2024 4:36pm
49 Views
Post# 35889686
New Press Release - Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate
New Press Release - Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate
OTTAWA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions has won a contract to support a Phase 2 Clinical Trial of ZYUS Life Science’s Trichomylin® softgel...
read article.
Comment on this Post
<< Previous
Bullboard Posts
Next >>
How one company is disrupting PoC testing
Sony’s Alpha 1 II: A new professional photography standard?
AI companies to invest in
Three micro-cap value stocks trading at peak pessimism
Gold vs. bitcoin, where should you invest?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario